Pathophysiology, diagnosis and treatment of Clostridium difficile infection

Keio Journal of Medicine

Volumn 48, Issue 4, 1999, Pages 169-174

  Castagliuolo, Ignazio ^a   LaMont, J Thomas ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Clolitis; Clostridium difficile; Enteric infection; Toxins

Indexed keywords

CLOSTRIDIUM TOXIN; COLESTYRAMINE; IMMUNOGLOBULIN; METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIOLOGY; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE SEVERITY; FECES ANALYSIS; HOSPITAL INFECTION; HUMAN; IMMUNOASSAY; LABORATORY TEST; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; REVIEW;

EID: 0033375785     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.48.169     Document Type: Review

References (45)

1. McFarland LV, Mulligan ME, Kwok RY, Stamm WE: Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-210
2. Hall IC, O'Toole E: Intestinal flora in newborn infants, with description of a new pathogenic anaerobe Bacillus difficilis. Am J Dis Child 1935; 49: 390-402
3. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB: Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978; 75: 778-782
4. McFarland LV, Elmer GW, Stamm WE, Mulligan ME: Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect Immun 1991; 59: 2456-2462
5. Tabaqchali S: Epidemiologic markers of Clostridium difficile. Rev Infect Dis 1990; 12(Suppl 2): S192-S199
6. Borriello SP: The influence of the normal flora on Clostridium difficile colonisation of the gut. Ann Med 1990; 22: 61-67
7. Tvede M, Rask-Madsen J: Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1: 1156-1160
8. Kelly CP, Pothoulakis C, LaMont JT: Clostridium difficile colitis. N Engl J Med 1994; 330: 257-262
9. Anand A, Glatt AE: Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17: 109-113
10. Tedesco FJ, Barton RW, Alpers DH: Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974; 81: 429-433
11. Triadafilopoulos G, Pothoulakis C, O'Brien MJ, LaMont JT: Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 1987; 93: 273-279
12. Sears CL, Kaper JB: Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev 1996; 60: 167-215
13. Hecht G, Pothoulakis C, LaMont JT, Madara JL: Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest 1988; 82: 1516-1524
14. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Mann M, Aktories K: The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 1995; 270: 13932-13936
15. Pothoulakis C, Gilbert RJ, Cladaras C, Castagliuolo I, Semenza G, Hitti Y, Montcrief JS, Linevsky J, Kelly CP, Nikulasson S, Desai HP, Wilkins TD, LaMont JT: Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest 1996; 98: 641-649
16. Castagliuolo I, LaMont JT, Letourneau R, Kelly C, O'Keane JC, Jaffer A, Theoharides TC, Pothoulakis C: Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 1994; 107: 657-665
17. Pothoulakis C, Castagliuolo I, LaMont JT, Jaffer A, O'Keane JC, Snider RM, Leeman SE: CP-96, 345, a substance P antagonist inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci USA 1994; 91: 947-951
18. Castagliuolo I, Riegler M, Pasha A, Nikulasson S, Lu B, Gerard C, Gerard NP, Pothoulakis C: Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis. J Clin Invest 1998; 101: 1547-1550
19. Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, LaMont JT, Pothoulakis C: Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 1994; 93: 1257-1265
20. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, Cosentini E, Feil W, Schiessel R, LaMont JT, Wenzl E: Clostridium difficile toxin B is more potent than toxin A in damaging human colonie epithelium in vitro. J Clin Invest 1995; 95: 2004-2011
21. McFarland LV: Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998; 16: 292-307
22. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R: Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994; 169: 127-133
23. Kim KH, Fekety R, Batts DH, Brown D, Cudmore M, Silva J Jr, Waters D: Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143: 42-50
24. Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN: Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998; 129: 1012-1019
25. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A: Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118: 633-637
26. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN: Nosocomial Clostridium difficile colonisation and disease. Lancet 1990; 336: 97-100
27. Bender BS, Bennett R, Laughon BE, Greenough WB 3d, Gaydos C, Sears SD, Forman MS, Bartlett JG: Is Clostridium difficile endemic in chronic-care facilities? Lancet 1986; 2: 11-13
28. Johnson S, Gerding DN, Olson MM, Weiler MD, Hughes RA, Clabots CR, Peterson LR: Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990; 88: 137-140
29. Larson HE, Barclay FE, Honour P, Hill ID: Epidemiology of Clostridium difficile in infants. J Infect Dis 1982; 146: 727-733
30. Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O'Keane CJ, Gong D, Gao N, Xu YL, Walker WA, LaMont JT: Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest 1992; 90: 822-829
31. Fekety R, Kim KH, Brown D, Batts DH, Cudmore M, Silva J Jr: Epidemiology of antibiotic-associated colitis: isolation of Clostridium difficile from the hospital environment. Am J Med 1981; 70: 906-908
32. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN: Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117: 297-302
33. Triadafilopoulos G, Hallstone AE: Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 1991; 101: 685-691
34. Doern GV, Coughlin RT, Wu L: Laboratory diagnosis of Clostridium difficile-associaled gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays. J Clin Microbiol 1992; 30: 2042-2046
35. DiPersio JR, Varga FJ, Conwell DL, Kraft JA, Kozak KJ, Willis DH: Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease. J Clin Microbiol 1991; 29: 2724-2730
36. De Girolami PC, Hanff PA, Eichelberger K, Longhi L, Teresa H, Pratt J, Cheng A, Letourneau JM, Thorne GM: Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A. J Clin Microbiol 1992; 30: 1085-1088
37. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT Jr: Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2: 1043-1046
38. Bolton RP, Culshaw MA: Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-1172
39. Young G, McDonald M: Antibiotic-associated colitis: why do patients relapse? Gastroenterology 1986; 90: 1098-1099
40. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN: Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43-50
41. Fekety R: Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92: 739-750
42. Tedesco FJ, Gordon D, Fortson WC: Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80: 867-868
43. Silva J Jr: Update on pseudomembranous colitis. West J Med 1989; 151: 644-648
44. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al.: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-1918
45. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C: Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64: 5225-5232